Premium
Soluble Interleukin 2 Receptor in Dialyzed Patients
Author(s) -
Shu KuoHsiung,
Lu YuanSan,
Cheng ChiHung,
Lian JongDa
Publication year - 1998
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.1998.05062.x
Subject(s) - continuous ambulatory peritoneal dialysis , medicine , hemodialysis , erythropoietin , gastroenterology , dialysis , receptor , peritoneal dialysis , renal function , interleukin 2 , immunology
Azotemic patients are usually characterized by a state of so‐called preactivation resulting in excessive expression of interleukin 2 receptors (IL‐2R) on T lymphocytes. The etiological mechanism of this preactivation is, however, still speculative. We studied the serum level of the soluble form of IL‐2R (sIL‐2R) in azotemic patients on either hemodialysis (HD) (n = 49) or continuous ambulatory peritoneal dialysis (CAPD) (n = 45). Both patient groups had significantly higher sIL‐2R levels (1,750 ± 664 U/ml in the HD group and 1,769 ± 647 U/ml in the CAPD group, respectively) p < 0.00001 as compared to the normal control group (511 ± 436 U/ml). However, there was no significant difference between the levels of the HD and CAPD group patients. When clinical parameters were studied for their influence on sIL‐2R levels, none of the following caused any significant changes; blood transfusion, type of dialyzer used, type of dialysis fluid used, treatment with erythropoietin, hepatitis B infection, or liver function profile. We conclude that chronic renal failure per se is the major cause of the preactivation of T lymphocytes. The modes of treatment and various clinical variables in these patients have no significant influence on sIL‐2R levels.